Barry, While you reach conclusions that are similar to mine and others, some of your data is a bit off. Agreed, we'll triple at a minimum next year, sales this year north of $70M, I think $80M ex Eu, next year revs north of $260.
Q1 folks on Iclusig were 325, end of April was 400. NRx is now
somewhat unreliable as it may include prescriptions for patients that are to 'new'.
I think what we hear on the cc will help us more accurately utilize the Rx numbers in predicting pod and revs.
Couldn't find Sobels blog. Link? thanks.